Shitara, K. Et Al. 2018. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET ONCOLOGY , vol.19, no.11 , 1437-1448.

Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H., Prokharau, A., ... Alsina, M.(2018). Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET ONCOLOGY , vol.19, no.11, 1437-1448.

Shitara, Kohei Et Al. "Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial," LANCET ONCOLOGY , vol.19, no.11, 1437-1448, 2018

Shitara, Kohei Et Al. "Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial." LANCET ONCOLOGY , vol.19, no.11, pp.1437-1448, 2018

Shitara, K. Et Al. (2018) . "Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial." LANCET ONCOLOGY , vol.19, no.11, pp.1437-1448.

@article{article, author={Kohei Shitara Et Al. }, title={Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial}, journal={LANCET ONCOLOGY}, year=2018, pages={1437-1448} }